课题基金 / 基金详情

Discovering Novel Therapeutics for Myotonic Dystrophy Type 1 (DM1)

Discovering Novel Therapeutics for Myotonic Dystrophy Type 1 (DM1)
发现 1 型强直性肌营养不良 (DM1) 的新疗法
批准号:
9409067
负责人:
Frederick M Ausubel
金额:
$15.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-08-01 至 2018-04-30

项目摘要

项目成果

Frederick M Ausubel的其他基金

相似基金

相关文献

中文摘要
翻译
肌营养不良症是一种涉及进行性肌肉的约30种遗传病的多样化集合 软弱,往往是致命的。最常见的成人肌营养不良是强直性肌营养不良I型(DM1 或MMD1),影响1:8,000至1:22,000人,导致严重残疾和缩短 寿命。DM1是由DMPK基因3‘-UTR(非翻译区)中的CUG重复序列扩展而来的 以积累有毒的核糖核酸分子为特征的。在大型DM1中还没有有效的治疗方法 部分是由于传统药物筛选试验的局限性。 Genma Biosciences(Genma Bio)已经开发出范式转换分析方法,以实现其长期目标 生产一种可用于临床试验的含铅DM1治疗化合物。在这项提议中,Genma Bio将进一步 开发并验证其高通量全动物线虫筛选技术,并将其与 在一个完整的、活的DM1疾病模型中进行尖端的自动运动监测。使用完整的动物 模型允许Genma Bio识别在起始点纠正了DM1缺陷的小分子点击 也就是说,RNA毒性是在其自然环境中发生的。命中应该包括几类复合词 只有在完整的生物体中才能获得,比如那些参与组织间信号传递的生物体。此外,由 在分析运动等DM1表型的恢复时,Genma Bio并不假定特定的 靶向并能够识别通过可能适用于多种相关的新机制作用的候选药物 精神错乱。具体地说,通过这些检测确定的DM1药物也可能对其他强直性肌强直有效 营养不良和由RNA重复扩增引起的约20种疾病,包括脊髓小脑性共济失调8型, 10、12和36,脆性X综合征和肌萎缩侧索硬化症(ALS)。的累积结果。 Genma Bio方法将是一套更广泛、更全面的高质量化合物 通过传统的筛选方法确定的具有最佳体内疗效和有利药物的 性质(低毒、生物利用度好)。有两个具体目标: 目的1:对运动分析方法进行改进,使之与线虫DM1 HTS平台兼容。 目标2:使用10,000种已知生物活性化合物进行原理验证筛选,以确定 修复DM1缺陷的分子。重要的是,在这方面的成功将带来一条药物发现管道 可概括为各种肌肉营养不良症。 此第一阶段方案将为第二阶段SBIR奠定基础,其中将包括更大尺寸的屏幕 以及优先处理化合物、哺乳动物试验和阐明作用机制的后续行动。
英文摘要
Muscular dystrophies are a diverse collection of ~30 genetic diseases that involve progressive muscle weakness and are often fatal. The most common adult muscular dystrophy is Myotonic Dystrophy Type I (DM1 or MMD1), which affects between 1:8,000 and 1:22,000 people, causing serious disabilities and a shortened lifespan. DM1 results from expanded CUG repeats in 3’-UTR (untranslated region) of the DMPK gene and is characterized by the accumulation of toxic RNA molecules. There are no effective treatments for DM1 in large part due to the limitations of traditional drug screening assays. Genma Biosciences (Genma Bio) has developed paradigm-shifting assays to enable its long-term goal of producing a lead DM1 therapeutic compound ready for clinical trials. In this proposal, Genma Bio will further develop and validate its high-throughput whole-animal C. elegans screening technology and merge it with cutting-edge automated movement monitoring in an intact, living DM1 disease model. Using a whole-animal model allows Genma Bio to identify small molecule hits in which DM1 defects are corrected at the point of origin of the disease, namely RNA toxicity occurring in its native context. Hits should include classes of compounds that are only accessible in an intact organism such as those involved in inter-tissue signaling. In addition, by assaying for the restoration of DM1 phenotypes such as movement, Genma Bio does not assume a specific target and can identify drug candidates acting by novel mechanisms potentially applicable to multiple related disorders. Specifically, DM1 drugs identified using these assays may also be effective against other myotonic dystrophies and the ~20 diseases caused by RNA repeat expansions including Spinocerebellar Ataxias types 8, 10, 12 and 36, Fragile X Syndrome, and Amyotrophic Lateral Sclerosis (ALS). The cumulative result of the Genma Bio approach will be a broader and more comprehensive set of high-quality compounds than would be identified through traditional screen approaches and that have optimal in vivo efficacy and favorable drug properties (low toxicity, good bioavailability). There are 2 specific aims: Aim 1: Modify the movement assays to be compatible with the C. elegans DM1 HTS platform. Aim 2: Perform a proof-of-principle screen using 10,000 known bioactive compounds to identify small molecules that rescue DM1 defects. Importantly, success here will result in a drug discovery pipeline generalizable to a variety of muscular dystrophies. This Phase I proposal will provide the foundation of a Phase II SBIR which will include a larger-scale screen and follow-up on prioritizing compounds, mammalian testing, and elucidation of the mechanism of action.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
First-in-class small molecule therapeutics to enhance gut barrier function in inflammatory bowel disease
  • 批准号:
    10251430
  • 项目类别:
  • 资助金额:
    $25.12万
  • 财政年份:
    2021
  • 负责人:
    Frederick M Ausubel
  • 依托单位:
First-in-class small molecules that enhance lung barrier function during acute respiratory distress syndrome (ARDS) as potential therapeutics for COVID-19
  • 批准号:
    10254996
  • 项目类别:
  • 资助金额:
    $25.0万
  • 财政年份:
    2021
  • 负责人:
    Frederick M Ausubel
  • 依托单位:
Identifying novel anti-infectives by high through-put screening in whole animals
  • 批准号:
    7764005
  • 项目类别:
  • 资助金额:
    $84.17万
  • 财政年份:
    2009
  • 负责人:
    Frederick M Ausubel
  • 依托单位:
Harvard-wide Program on Antibiotic Resistance
海外基金